This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Protti, M. P. Articles by Rugarli, C. Search for Related Content PubMed PubMed Citation Articles by Protti, M. P. Articles by Rugarli, C.

Particulate Naturally Processed Peptides Prime a Cytotoxic Response against Human Melanoma in Vitro¹

Laboratorio di Immunoterapia Adottiva [M. P. P., M. A. I., A. A. M., G. Co., S. H., M. B., C. R.], Laboratorio di Tecniche Separative [C. A.], and Unità di Immunochimica, Departimento Biotecnologie [P. D., G. Ca.], Istituto Scientifico H. San Raffaele, via Olgettina 60, 20132 Milan, and Cattedra di Medicina Interna II, Università degli Studi di Milano, 20100 Milan [C. R.], Italy

For an efficient antitumor cytotoxic response, tumor antigenic peptides need to be presented by professional antigen-presenting cells in association with MHC class I molecules. We established in vitro short-term human CTL lines from healthy and melanoma-bearing subjects, using as antigen-presenting cells autologous adherent cells after phagocytosis of latex beads coated with melanoma peptides. Melanoma peptides were obtained by acid extraction of melanoma cells that matched with donor peripheral blood mononuclear cells, at least for one HLA-A allele. The cytotoxic activity of the lines was specific for the melanoma from which peptides were obtained and for melanoma sharing HLA alleles. These results demonstrate that a complex mixture of naturally processed melanoma peptides conjugated to a phagocytic substrate that targets them into the MHC class I pathway of adherent cells can prime a CTL response in healthy subjects in vitro, and that peptides from allogeneic tumors may be used to propagate CTL in melanoma patients. Our data support the feasibility of active and passive vaccination procedures with nonliving vaccines in cancer patients.

¹ This work was supported by the Fondazione Centro San Raffaele del Monte Tabor, by Progetto Finalizzato Applicazioni Cliniche Ricerca Oncologica Grant 9202374 PF39 from the Consiglio Nazionale delle Ricerche (to C. R.), and by Grant 324/95 from the Associazione Italiana Ricerca sul Cancro (to C. R.). P. D. and G. C. are supported by the Associazione Italiana Ricerca sul Cancro.

² To whom requests for reprints should be addressed.

Received 11/27/95. Accepted 1/29/96.

This article has been cited by other articles:

				E. Tassi, V. Facchinetti, S. Seresini, A. Borri, G. Dell'Antonio, C. Garavaglia, G. Casorati, and M. P. Protti Peptidome from Renal Cell Carcinoma Contains Antigens Recognized by CD4+ T Cells and Shared among Tumors of Different Histology. Clin. Cancer Res., August 15, 2006; 12(16): 4949 - 4957. [Abstract] [Full Text] [PDF]

				G. Consogno, S. Manici, V. Facchinetti, A. Bachi, J. Hammer, B. M. Conti-Fine, C. Rugarli, C. Traversari, and M. P. Protti Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 Blood, February 1, 2003; 101(3): 1038 - 1044. [Abstract] [Full Text] [PDF]

				R. E. Clark, I. A. Dodi, S. C. Hill, J. R. Lill, G. Aubert, A. R. Macintyre, J. Rojas, A. Bourdon, P. L. R. Bonner, L. Wang, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein Blood, November 15, 2001; 98(10): 2887 - 2893. [Abstract] [Full Text] [PDF]

				I. Miconnet, I. Coste, F. Beermann, J.-F. Haeuw, J.-C. Cerottini, J.-Y. Bonnefoy, P. Romero, and T. Renno Cancer Vaccine Design: A Novel Bacterial Adjuvant for Peptide-Specific CTL Induction J. Immunol., April 1, 2001; 166(7): 4612 - 4619. [Abstract] [Full Text] [PDF]

				M. A. Imro, S. Manici, V. Russo, G. Consogno, M. Bellone, C. Rugarli, C. Traversari, and M. P. Protti Major Histocompatibility Complex Class I Restricted Cytotoxic T Cells Specific for Natural Melanoma Peptides Recognize Unidentified Shared Melanoma Antigen(s) Cancer Res., May 1, 1999; 59(10): 2287 - 2291. [Abstract] [Full Text] [PDF]

				S. Manici, T. Sturniolo, M. A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, et al. Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 J. Exp. Med., March 1, 1999; 189(5): 871 - 876. [Abstract] [Full Text] [PDF]

				M. Ostankovitch, A. Buzyn, D. Bonhomme, F. Connan, D. Bouscary, F. Heshmati, F. Dreyfus, J. Choppin, and J.-G. Guillet Antileukemic HLA-Restricted T-Cell Clones Generated With Naturally Processed Peptides Eluted From Acute Myeloblastic Leukemia Blasts Blood, July 1, 1998; 92(1): 19 - 24. [Abstract] [Full Text] [PDF]